Insmed Incorporated (NASDAQ:INSM) Receives $81.40 Average Price Target from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have earned a consensus rating of “Buy” from the sixteen brokerages that are presently covering the company, Marketbeat.com reports. Sixteen investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $81.53.

INSM has been the topic of several recent research reports. TD Cowen lifted their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. Morgan Stanley raised their price target on Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Stifel Nicolaus upped their price objective on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Mizuho raised their target price on shares of Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, June 7th.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. UBS Group AG lifted its holdings in shares of Insmed by 145.6% during the 4th quarter. UBS Group AG now owns 300,181 shares of the biopharmaceutical company’s stock worth $9,303,000 after acquiring an additional 177,981 shares during the period. Eagle Asset Management Inc. increased its stake in shares of Insmed by 5.7% in the 4th quarter. Eagle Asset Management Inc. now owns 548,633 shares of the biopharmaceutical company’s stock valued at $17,002,000 after purchasing an additional 29,555 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Insmed during the 4th quarter worth $1,702,000. Rafferty Asset Management LLC lifted its position in shares of Insmed by 17.4% during the 4th quarter. Rafferty Asset Management LLC now owns 321,087 shares of the biopharmaceutical company’s stock worth $9,950,000 after buying an additional 47,563 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Insmed in the fourth quarter valued at about $27,891,000.

Insmed Stock Performance

INSM opened at $71.40 on Friday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The company has a market capitalization of $10.61 billion, a price-to-earnings ratio of -13.65 and a beta of 1.11. The business’s 50-day moving average price is $74.07 and its two-hundred day moving average price is $54.70. Insmed has a 1 year low of $21.92 and a 1 year high of $80.53.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The business’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.78) EPS. Equities analysts expect that Insmed will post -5.42 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.